BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU
March 15 2006 - 4:04PM
PR Newswire (US)
All Primary and Secondary Endpoints Met NOVATO, California, and
GENEVA, Switzerland, March 15 /PRNewswire-FirstCall/ -- BioMarin
Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Serono (virt-x: SEO
and NYSE: SRA) announced today positive results of a Phase 3,
double-blind, placebo-controlled clinical study of Phenoptin(TM)
(sapropterin dihydrochloride), an investigational oral small
molecule for the treatment of phenylketonuria (PKU). Results
confirm that all pre-specified primary and secondary endpoints were
met and data from the Phase 3 study demonstrate a statistically
significant reduction at six weeks in blood phenylalanine (Phe)
levels (p